Activation of the PI3K-Akt-mTOR pathway is critical for the cellular progression of renal cell carcinoma, but many tested PI3K-mTOR kinase inhibitors failed to significantly improve the clinical symptoms of RCC patients (Husseinzadeh and Garcia, 2011; Pal and Quinn, 2013). This evidence concerns the gene PIK3CD and renal cell carcinoma.